We are live on ! Find out more
TPI

TIANYIN PHARMACEUTICAL
TPI

Delisted

TPI was delisted on the 29th of April, 2016.

6 hedge funds and large institutions have $4.37M invested in TIANYIN PHARMACEUTICAL in 2013 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

53% more capital invested

Capital invested by funds: $2.86M → $4.37M (+$1.5M)

0% more funds holding

Funds holding: 66 (0)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
6
Holders Change
Holders Change %
0%
% of All Funds
0.19%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
Increased
3
Reduced
1
Closed
Calls
Puts
Net Calls
Net Calls Change

Top Sellers

Rank Fund Capital Flow
1
CCB
Cutter & Co Brokerage
Missouri
-$3.23K

TPI Hedge Fund Activity: Q3 2013 in Review

6 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in TIANYIN PHARMACEUTICAL (TPI) for Q3 2013, worth a combined $4.37M — up 53% from $2.86M a quarter earlier.

Fund positioning in TPI was balanced in Q3 2013: 0 funds opened new positions, 0 closed out, 3 added to existing stakes and 1 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $8.05K. The largest seller was Cutter & Co Brokerage, cutting an estimated $3.23K.

  • 6 institutional investors held TIANYIN PHARMACEUTICAL (TPI) as of Q3 2013, unchanged from Q2 2013.
  • Funds reported $4.37M of TIANYIN PHARMACEUTICAL stock for Q3 2013, up 53% quarter-over-quarter.
  • 0 funds opened new TIANYIN PHARMACEUTICAL positions in Q3 2013 and 0 closed out.
  • The largest TIANYIN PHARMACEUTICAL buyer in Q3 2013 was Renaissance Technologies, an estimated $8.05K added.
  • The largest TIANYIN PHARMACEUTICAL seller in Q3 2013 was Cutter & Co Brokerage, an estimated $3.23K sold.

Based on aggregated 13F filings for Q3 2013.